1. Werren, Elizabeth A, Rodriguez Bey, Guillermo, Majethia, Purvi, Bielas, Stephanie L, Shukla, Anju. . Biallelic EPB41L3 variants underlie a developmental disorder with seizures and myelination defects. In Brain : a journal of neurology, 147, 4033-4042. doi:10.1093/brain/awae299. https://pubmed.ncbi.nlm.nih.gov/39292993/
2. Zeng, Rong, Huang, Jun-Peng, Li, Xu Feng, Zheng, Yan-Fang, Zhang, Ji-Ren. 2016. Epb41l3 suppresses esophageal squamous cell carcinoma invasion and inhibits MMP2 and MMP9 expression. In Cell biochemistry and function, 34, 133-41. doi:10.1002/cbf.3170. https://pubmed.ncbi.nlm.nih.gov/26916087/
3. Tuerxun, Gulixian, Li, Wenyun, Abudurexiti, Guligeina, Tuerdi, Awahan, Abulizi, Guzalinuer. 2024. EPB41L3 Inhibits the Progression of Cervical Cancer Via the ERK/p38 MAPK Signaling Pathway. In Molecular biotechnology, , . doi:10.1007/s12033-024-01172-z. https://pubmed.ncbi.nlm.nih.gov/38907071/
4. Bernkopf, Dominic B, Williams, Elizabeth D. . Potential role of EPB41L3 (protein 4.1B/Dal-1) as a target for treatment of advanced prostate cancer. In Expert opinion on therapeutic targets, 12, 845-53. doi:10.1517/14728222.12.7.845. https://pubmed.ncbi.nlm.nih.gov/18554153/
5. Tuerxun, Gulixian, Abulimiti, Tangnuer, Abudurexiti, Guligeina, Zhang, Yuanyuan, Abulizi, Guzalinuer. . Over-expression of EPB41L3 promotes apoptosis of human cervical carcinoma cells through PI3K/AKT signaling. In Acta biochimica Polonica, 69, 283-289. doi:10.18388/abp.2020_5649. https://pubmed.ncbi.nlm.nih.gov/35569139/
6. Gu, Yuan Yuan, Zhou, Guan Nan, Li, Yao, Ding, Jing Xin, Hua, Ke Qin. 2022. HDAC10 Inhibits Cervical Cancer Progression through Downregulating the HDAC10-microRNA-223-EPB41L3 Axis. In Journal of oncology, 2022, 8092751. doi:10.1155/2022/8092751. https://pubmed.ncbi.nlm.nih.gov/35075362/